ROCKVILLE, Md., April 26 /PRNewswire-FirstCall/ -- Protiveris Inc., a bio- nanotechnology company commercializing nano-mechanical technologies to facilitate biomolecular research, today announced that it has successfully completed installation of its VeriScan(TM) 3000 Biosensor System at the Lombardi Comprehensive Cancer Center at Georgetown University. Dr. Andrew Quong, who leads the Center's Division of Nanotechnology and Integrative Cancer Biology in the Department of Oncology, will direct a collaborative effort to explore the use of nanotechnologies in cancer research using Protiveris's microcantilever-based products. "This represents a significant milestone for Protiveris as it is the first VeriScan System collaboration with specific clinical cancer research applications," commented Robert Menzi, Chief Operating Officer at Protiveris. "Dr. Quong and his team at Lombardi are uniquely qualified to develop new approaches using our nano-technology products. Dr Quong understands the full range of scientific and technological requirements -- from engineering and physics to chemistry and biology -- necessary to develop successful and innovative approaches to cancer research." "This as a unique opportunity to bring the latest advances in the emerging field of nanotechnology to cancer diagnosis and therapeutic stratification," added Dr Quong. "The Protiveris VeriScan Biosensor System affords us the potential to perform highly sensitive multiplexed assays for both laboratory and clinical use on a stable, well engineered platform." The VeriScan 3000 protein biochip and optical reader utilize arrays of microcantilevers with customizable surfaces to measure, label-free and in real-time, multiplex and distinct protein, antibody, antigen, or DNA biomolecular interactions. Protiveris is currently installing this system in forward-looking research facilities in the United States and Europe. About Protiveris, Inc. Protiveris is committed to establishing the standard of performance for proteomic research tools. The VeriScan(TM) 3000 bench-top biochip system measures and analyzes biomolecular and chemical interactions to enable more efficient and accurate research outcomes. The biochip utilizes arrays of microcantilevers with customizable surfaces to detect interactions between proteins, antibodies, antigens, or DNA. This label-free system provides researchers with the ability to create high content assays that deliver real time data. More information about Protiveris, their technology, products, and services can be found at the company's web site at http://www.protiveris.com. About the Lombardi Comprehensive Cancer Center Established in 1970, the Lombardi Comprehensive Cancer Center is named for the legendary Green Bay Packers and Washington Redskins coach Vince Lombardi, who was treated for cancer at Georgetown University Hospital. What began as a small clinic grew over the years to become a state-of-the-art cancer center. In 1990, the Lombardi Center won the designation of "Comprehensive Cancer Center" from the National Cancer Institute (NCI). To obtain this designation, a center must meet strict research, clinical trials and community outreach criteria. In 2003, Lombardi's comprehensive cancer center status was renewed by the NCI. Lombardi's internationally renowned clinical team offers the latest treatments for virtually every type of cancer, with a particular emphasis in solid tumors and adult and pediatric hematologic cancers. More information about Lombardi Comprehensive Cancer Center can be found at http://lombardi.georgetown.edu.
SOURCE Protiveris Inc.